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ABSTRACT
Introduction. Desferoxamine is one of iron chelating drugs. With the chelation of iron, phosphatidylinositol -3- 
kinase inhibitor is inhibited so that the release of endothelial nitric oxide synthesis phosphorylation is uninhibited. 
We examined whether addition of desferoxamine would lead to fracture healing enhancement.
Material and methods. Twenty four Spargue Dawley mice were used in the study. Their tibias were fractured and 
2 mm defect were created. The fractures were then fixated using intramedullary K-wire. They were then allocated 
into four groups: group I received nothing, group II, III, and IV received desferoxamine since the first, fifteenth, 
and twenty second day respectively. The radiological and histological scores were measured at the sixth week and 
analyzed using ANOVA test.
Results.  There were significant differences in radiological and histological scores among groups. (p = 0.024 and p 
= 0.007 respectively)
Conclusions. Addition of desferoxamine since the fifteenth but not after the twenty second days enhanced fracture 
healing.
Keywords:  desferoxamine, fracture healing, phostidylinositol 3 - kinase inhibitor, endothelial nictric oxide syntesis
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Efek Desferoksamin terhadap Penyembuhan Fraktur Tibia dengan Defek 2 mm 
pada Tikus Sprague Dawley 
ABSTRAK
Pendahuluan. Desferoksamin adalah suatu chelating agent. Penarikan besi oleh desferoksamin menyebabkan 
kerja enzim phosphatidylinositol -3- kinase inhibitor terhambat. Hambatan enzim tersebut membuat phosphorilasi 
endothelial nitric oxide synthesis berlangsung tanpa hambatan. Penelitian ini menilai efek pemberian desferoksamin 
terhadap penyembuhan fraktur.
Bahan dan cara kerja. Dua puluh empat ekor tikus putih Sprague Dawley yang dipatahkan dan dibuat defek sebesar 
2 mm pada tibianya diikutkan dalam penelitian. Setelah difiksasi intrameduler dengan menggunakan K-wire, tikus 
tersebut dialokasikan ke dalam empat kelompok. Kelompok I tidak mendapatkan terapi desferoksamin, kelompok 
II mendapat desferoksamin sejak hari pertama, kelompok III dan IV mendapatkan desferoksamin sejak hari ke lima 
belas dan dua puluh dua. Pada minggu keenam, dilakukan pengukuran skor radiologis dan skor histologis. Kedua 
skor tersebut dibandingkan antar kelompok dengan menggunakan uji ANOVA.
Hasil. Terdapat perbedaan yang bermakna antar kelompok dalam skor radiologis (p = 0,024) dan skor histologis (p 
= 0,007).
Simpulan. Pemberian desferoksamin sejak hari ke-lima belas tetapi sebelum hari ke-dua puluh dua mempercepat 
penyembuhan fraktur.
Kata kunci:  desferokasmin, penyembuhan fraktur, phostidylinositol 3 - kinase inhibitor, endothelial nictric oxide 
syntesis
Introduction
Fracture healing involves migration, proliferation, 
and differentiation of numerous types of cells such as 
endothelial cells, fibroblasts, chondroblasts, osteoblasts, 
and osteoclasts. Bone formation occurs through two 
different processes, depending on the stability.1 In 
absolute stability, bone formation occurs through 
intramembranous ossification. In relative stability, bone 
formation occurs through endochondral ossification. 
In endochondral ossification, healing process begin 
with formation of hematoma. Hematoma contains 
angiogenesis factors.2 Hematoma will also isolate tissue 
perfusion, leading to low oxygen pressure and regional 
hypoxia. Formation of callus, deposition of cartilage and 
bone will worsen the hypoxia.3
Vascular endothelial growth factor (VEGF) is a 
potent mediator in hypoxic conditions that can induce 
angiogenesis process. It accumulates in the hematoma 
after fracture.4,5 Recent studies showed that VEGF might 
serve as an important mediator during angiogenesis and 
bone development process including differentiation of 
osteoblasts and osteoclasts recruitment.6,7
Endogenous VEGF is secreted from endothelial cells, 
fibroblasts and osteoblasts. VEGF stimulates endothelial 
cells to synthesize osteogenic factors, thus acting 
indirectly in bone formation. During the bone healing 
process, VEGF is required not only for the formation 
of blood vessels, but also for the callus formation 
and mineralization.2 VEGF induces angiogenesis in 
endochondral ossification and normal fracture healing.8,9 
VEGF also plays an important role in fracture healing.10,11
The purpose of this study was to determine the effect 
of desferoxamine in fracture healing with bone defect of 
two millimeter.
Materials and methods
This was a post-test only control group animal study. 
Twenty eight Sprague-Dawley rats weighted 200-250 
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g were included in the study. The study was conducted 
at Animal Nutrition Laboratory, Fakultas Kedokteran 
Universitas Indonesia from June 2010 to September 
2010. Rats with disability, infection, and protrusion of 
implant were excluded from the study.
After intraperitoneal anesthesia using 40 mg/kgBW 
ketamine, the left leg of the rats was fracturized. The 
fracture was retrogradely fixated by intramedullary 
1.0 mm Kirschner-wire. The rats were then randomly 
allocated into 4 groups: group one which received no 
desferoxamine, group two which received desferoxamine 
injection since the first day, group three which received 
desferoxamine injection since the second week, and group 
four which received desferoxamine at the beginning of 
the third week. Dose of desferoxamine used in this study 
was 30 mg/kgBW. All rats received similar postoperative 
treatment consisting of ampicillin and mefenamic acid 
100 mg/kgBW/day divided into three dosing. 
The rats underwent radiological evaluation at the 
sixth week. Radiological score was determined from 
the radiographs using the scoring system introduced by 
Tiedeman.12 Following radiological evaluations, the rats 
were scarified for histological evaluation. Histological 
score according to Salkeld and Marino13 was determined 
from the histological slide. The differences in radiological 
and histological score among groups were analyzed 
using one way ANOVA test. 
Results
At the sixth weeks, two rats in the control group died, 
(a) (b)
(c) (d)
Figure 1. Radiographs at the sixth week of treatment. No callus was seen in group I (a). In group II, minimal callus 
was visible (b). The fracture line was hardly visible in group III (c) while it was still visible in group IV (d).
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leaving 26 six rats for further analysis. Figure 1 showed 
the radiological imaging from each group while the 
radiological scores were outlined in table 1. ANOVA 
test revealed significant differences among groups. (p = 
0.024) Post-hoc analysis test revealed that the difference 
occurred between group I and group III. (p = 0.02)
Histological finding in each group was shown in figure 
2 and the scores were outlined in table 1. The ANOVA 
test revealed significant difference among groups with 
a p value of 0.007. Post-hoc analysis revealed that the 
difference occurred between group III and IV. (p = 0.02)
Discussions
Both mechanical and biological factors play important 
roles in fracture healing. Mechanical factor provide 
Table 1. Radiological and histological score of each group
Group N Radiological 
score (Mean ± 
SD)
Histological score 
(Mean ± SD)
I 6 4.2 ± 1.32 12.66 ± 1.50
II 6 6.5 ± 1.87 13.50 ± 1.87
III 6 7.5 ± 1.97 15.66 ± 1.21
IV 6 6.0 ± 1.67 12.83 ± 1.16
(a) (b)
(c) (d)
Figure 2. Histologic finding in each group. Compared to group I (a), II (b), and IV(d), group III (c) showed more 
mature bone.
immobilization for the fracture while biological factor 
stimulate and enhance the vascularization. 
In our study, the mechanical factor was provided 
by fixation with intramedullary K-wire. Fixation with 
intramedullary K-wire provides relative stability for 
the fracture, although it could not control rotational 
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instability.
We found that the healing process was most advanced 
in group treated with desferoxamine on the fifteenth day. 
On the fifteenth day, the process of neovascularization 
begins. Desferoxamine increases endothelial nitric oxide 
synthesis (eNOS) phosphorylation in endothelial cells 
which was inhibited by phosphatidylinositol 3 -kinase 
inhibitor. Phosphatidylinositol 3 -kinase inhibitor 
requires Fe in order to work, therefore chelating of Fe 
by desferoxamine inhibits the enzyme. After the 22 day, 
the endothelial cells have been matured, so addition of 
desferoxamine play little role. 
Conclusions
Addition of desferoxamine since the fifteenth but not 
after the twenty second days enhanced fracture healing.
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